AN2 Therapeutics, a biopharmaceutical company based in Menlo Park, California, focuses on developing treatments for serious infectious diseases, with epetraborole as a potential oral treatment for non-tuberculous mycobacterial lung disease. The company went public on March 25, 2022, and employs 41 people.